BIOREGULATORY AGENTS FOR MENOPAUSAL WOMEN

Download full text PDF
DOI: https://doi.org/10.29296/25419218-2018-03-03
Issue: 
3
Year: 
2018

E.V. Konopleva Saint Petersburg Chemopharmaceutical University; 14, Prof. Popov St., Saint Petersburg 197376, Russian Federation

The choice of a treatment method for menopausal syndrome (MS) is always individual. If it is impossible to use hormonal drugs or the patient does not want to take them, the physician has a wide range of non-hormonal drugs for the correction of the manifestations of MS. It is most difficult to select effective non-hormonal agents for women with previous hormonal therapy, severe concomitant somatic pathology, and a long duration of MS. Bioregulatory therapy for MS is based on the activation of the body’s own reserves. The combined bioregulatory drug Traumeel S affects the inflammatory process, by involving different mechanisms, including tissue regeneration. The bioregulatory drug Klimakt-Heel contributes to the safe and effective prevention of the manifestations of menopausal disorders, estrogen-deficiency states and ensures the correction of the negative manifestations of menstrual dysregulation. The nature of autonomic disorders in MS can vary considerably in severity – from minor emotional autonomic disorders to severe psychoautonomic crises occurring as frank panic attacks. The use of the bioregulatory medications Traumeel S and Klimakt-Heel" in women with MS complicated by severe psychoautonomic crises (panic attacks) can be a worthy choice in terms of the validity of the optimal treatment regimen. The use of bioregulatory drugs does not rule out treatment with other drugs.
Keywords: 
menopausal syndrome
therapy
bioregulatory drugs
activation of the body’s protective forces
References: 
  1. Budanov P.V., Levakov S.A., Sheshukova N.A., Shemanaeva T.V. Patogeneticheskaya i akademicheskaya preemstvennost` e`ffektivnosti terapii funkcional`nyh sostoyaniy u zhenshhin. Lechashhiy vrach, 2018; 3: 69–71.
  2. Rukovodstvo po ambulatorno-poliklinicheskoy pomoshhi v akusherstve i ginekologii. Pod red. V.I. Kulakova, V.N. Prilepskoy, V.E. Radzinskogo. M.: GE`OTAR-Media, 2006; 1036.
  3. Lebedeva O., Pahomov S., Nagornyy A., Golovchenko O. Zamestitel`naya gormonal`naya terapiya pri klimaktericheskom sindrome u zhenshhin. Vrach. 2015; 6: 10–5.
  4. Smetnik V.P., Kulakov V.I. Rukovodstvo po klimakteriyu. M.:2001; 685.
  5. Konopleva E.V. Klinicheskaya farmakologiya. Chast` 2. M.: Yurayt, 2017; 61.
  6. Konopleva E.V. Farmakologiya. M.: Yurayt, 2017; 324.
  7. Johnston J.M., Colvin A., Johnson B.D. et al. Comparison of SWAN and WISE menopausal status classification algorithms. J. Womens Health, 2006; 15: 1184–94.
  8. Belyalov F.I. Dvenadcat` tezisov komorbidnosti. Klinicheskaya medicina, 2009; 12: 69–71.
  9. Belyalov F.I. Lechenie vnutrennih bolezney v usloviyah komorbidnosti. I.: RIO IGMAPO, 2012; 310.
  10. Sedova N.V. Panicheskie ataki v klinicheskoy kartine patologicheskogo klimaksa (kliniko-neyrofiziologicheskiy analiz). Avtoref. Kand. med. nauk. M.: 2013; 24.
  11. Lyaymbah H. Antigomotoksicheskaya terapiya i normalizaciya vegetativnyh disfunkciy. Biologicheskaya medicina, 2016; 1: 6–8
  12. Konopleva E.V. Vvedenie v klinicheskuyu farmakologiyu i farmakoterapiyu (serdechno-sosudistye sredstva). SPb.: «Prospekt Nauki», 2018; 45.
  13. Hazelen R. Integrativnyy obzor dokazatel`stv e`ffektivnosti antigomotoksichnogo preparata «Traumel`». RMZh, 2017; 3:185–97.
  14. Konopleva E. V. Klinicheskaya farmakologiya.Chast` 1. M.: Yurayt, 2017; 88.
  15. Berike V. Materia Medica gomeopaticheskih preparatov. M.: Gomeopaticheskaya medicina, 2000; 384.
  16. Obshhaya terapiya. Katalog preparatov firmy «Heel`». Pod red. A.A. Mar`yanovskogo, S.A. Rabinovicha, S.O. Serebryakova. M.: Arnebiya, 2014; 400.
  17. Portnova N.I. Negormonal`nye metody lecheniya klimaktericheskogo sindroma. Kremlevskaya medicina. Klinicheskiy vestnik. Tematicheskiy vypusk: poliklinicheskaya pomoshh`, 2010; 84–9.